#SMART

Previous research has shown that long interruptions are not safe—but what about shorter, more closely monitored gaps in treatment?

The increasing mastery over the virus is one of humanity’s crowning achievements.

Treatments to reduce inflammation could help make HIV even less of a threat to health than antiretrovirals can alone.

Celebrating 20 years of effective HIV treatment

Here’s a timeline of the highlights.

There is a link between low-level elevations of markers indicating systemic inflammation and the development of type 2 diabetes among HIV-posi...

Susan Murphy developed the Sequential Multiple Assignment Randomized Trial (SMART) model.

SMART is run by and for women with HIV.

People on antiretrovirals who have an undetectable viral load and a CD4 count of at least 500 appear to have no increased death risk.

Successfully controlling HIV and keeping CD4 levels high may reduce the risk of death to that of the general population.

Researchers of a new study, published online June 24 in the Journal of Acquired Immune Deficiency Syndromes, found similar rates of...

There is no association between the use of ViiV Healthcare’s nucleoside analogue abacavir—found in Ziagen, Epzicom and Trizivir—and heart....

HIV-positive women and men do not appear to have increased signs of cardiovascular inflammation when they take abacavir (found in Ziagen, Epzi...

Interrupting antiretroviral (ARV) therapy may be “particularly hazardous” for people living with HIV and chronic hepatitis B virus...

A study conducted in Denmark suggests abacavir (found in Ziagen, Epzicom and Trizivir) increases the risk of a heart attack by 95 percent...

Use of the nucleoside reverse transcriptase inhibitor (NRTI) abacavir is not associated with an increased risk of a heart attack or stroke.